ClinicalTrials.gg
WithdrawnNCT05268497Updated Apr 27, 2025

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

A Phase 1 interventional study of Esketamine and Cognitive Behavioral Therapy (CBT) in Depression, sponsored by Janssen Research & Development, LLC. Withdrawn at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Why this study was withdrawn
due to budget decision and wanting to pursue other research priorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing esketamine in Depression — 11 open to participants now, 12 under way, 1 of them phase 3. Esketamine · Depression.

Enrollment
28th of 28
0 · median 156
Started
2022
with 3 others
Phase 1
4 of 28
2 open now
Registered
13th of 28
by date
Lead sponsor
2 of 28
Janssen Research & Development, LLC

Among the 28 studies testing esketamine in Depression, this one is the 28th largest by enrollment, is one of 4 that started in 2022, is one of 4 in phase 1, and was the 13th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

11 of the 28 studies testing esketamine in Depression are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing esketamine in Depression, or all of them as a file.
02

Study summary

The purpose of this study is to explore feasibility of combining clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app with esketamine therapy in participants with Treatment-resistant Depression.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator
  • Participant must meet the (5th edition) (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent MDD, without psychotic features, based upon clinical assessment confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Participant must have had nonresponse to greater than or equal to (>=) 2 different oral antidepressant treatments of adequate dose and duration in the current episode of depression
  • Participant must be currently taking an oral antidepressant.
  • Participant must be comfortable with self-administration of nasal spray medication and be able to follow the nasal spray administration instructions provided

Exclusion criteria

Exclusion Criteria:

  • Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral/bilateral ECT
  • Participant has a current or prior diagnosis of a psychotic disorder or MDD with psychotic features, bipolar or related disorders (confirmed by the MINI), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
  • Participant has a history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria, except nicotine or caffeine, within 6 months before the start of the screening phase. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
  • Participant has any anatomical or medical condition that, per the investigator's clinical judgment based on assessment, may impede delivery or absorption of nasal spray study drug
  • Participant has known allergies, , intolerance, or to esketamine/ketamine and/or its
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Esketamine

    Participants will receive esketamine nasal spray (Dose 1 or Dose 2) twice weekly for 4 weeks (Induction Phase), followed by once a week dose (Dose 1 or Dose 2) for 8 weeks (Maintenance Phase), in conjunction with an oral antidepressant. Clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app will be administered by a clinician following esketamine dosing once the participants is considered ready to engage in therapy, based on the clinician judgement of CBT readiness.

    Drug: Esketamine · Behavioral: Cognitive Behavioral Therapy (CBT) · Drug: Antidepressant

Interventions

  • Esketamine will be self-administered as nasal spray.

    Also known as: SPRAVATO, JNJ-54135419, Non-Investigational Medicinal Product/Auxiliary Medicinal Product (NIMP/AxMP)

  • BehavioralCognitive Behavioral Therapy (CBT)

    Clinician-directed CBT supplemented by the Mindset app will be administered.

  • DrugAntidepressant

    Antidepressant will be administered orally.

06

What researchers measure

Primary outcomes

  1. System Usability Scale (SUS) Scores (Participants)

    The SUS provides a reliable tool for measuring the usability of a wide variety of products and services, including hardware, software, mobile devices, websites, and applications. It consists of a 10-item questionnaire with five response options for respondents; from strongly agree to strongly disagree.

    Time frame: Week 13

  2. Net Promoter Scale Scores (Participants)

    Net promoter score is a market research measure that asks respondents to rate the likelihood that they would recommend a company, product, or a service to a friend or colleague. Responses are on a rating on a scale of 0 (not at all likely) to 10 (extremely likely).

    Time frame: Week 13

  3. Exit Survey

    Exit survey is a survey including ratings regarding participant impression of features of the Mindset app.

    Time frame: Week 13

  4. Time Spent on Mindset App

    Time spent on Mindset app will be reported for participants.

    Time frame: From Week 2 up to Week 13

  5. Number of Times Mindset App Used

    Number of times the Mindset app is used will be reported.

    Time frame: From Week 2 up to Week 13

  6. Pattern of Mindset App Used

    Pattern of Mindset app usage will be reported.

    Time frame: From Week 2 up to Week 13

  7. CBT Therapist Assessment of Completion of Action Plan

    Assessment of completion of action plan will be done by CBT therapists through rating on a 5-point likert scale of the participant's progress.

    Time frame: From Week 2 up to Week 13

  8. Participant Interviews

    Optional qualitative feedback from study participants (participant's interviews) on the usefulness of the Mindset in conjunction with esketamine will be reported.

    Time frame: Week 20

  9. SUS Scores (CBT Therapists)

    The SUS provides a reliable tool for measuring the usability of a wide variety of products and services, including hardware, software, mobile devices, websites, and applications. It consists of a 10-item questionnaire with five response options for respondents; from strongly agree to strongly disagree.

    Time frame: Up to 14 months (at the end of study)

  10. Net Promoter Scale Scores (CBT Therapists)

    Net promoter score is a market research measure that asks respondents to rate the likelihood that they would recommend a company, product, or a service to a friend or colleague. Responses are on a rating on a scale of 0 (not at all likely) to 10 (extremely likely).

    Time frame: Up to 14 months (at the end of study)

  11. Frequency of Use of Clinician Dashboard Used

    Frequency of use of clinician dashboard will be reported.

    Time frame: From Week 2 up to Week 13

  12. Clinician Feedback

    Qualitative feedback on clinician dashboard and participant use of the mindset app in conjunction with esketamine (clinician feedback) will be reported.

    Time frame: Up to 14 months

  13. Percentage of Participants Able to Engage in CBT

    Percentage of participants able to engage in CBT on the day of dosing for each week of the study and overall will be reported.

    Time frame: From Week 2 up to Week 13

  14. Timing of CBT Readiness after Dosing

    Timing of CBT readiness after dosing will be reported. Determination of readiness will be based on clinician judgement of CBT readiness to engage in CBT based on alertness and ability to concentrate after dosing.

    Time frame: From Week 2 up to Week 13

Secondary outcomes

  1. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Scale Score

    The MOAA/S will be used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American Society of Anesthesiologists (ASA) continuum. The MOAA/S scores range from 0=no response to painful stimulus (corresponds to ASA continuum for general anesthesia) to 5=readily responds to name spoken in normal tone (awake; corresponds to ASA continuum for minimal sedation).

    Time frame: Pre-dose, 40 minutes and 90 minutes post-dose up to Week 4

  2. Clinician Administered Dissociative States Scale (CADSS) Score

    The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. The CADSS consists of 23 subjective items, divided into 3 components: depersonalization (Items 3 to 7, 20, and 23), derealization (Items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia (Items 14, 15, and 22). Participant's responses are coded on a 5-point scale (0=not at all through to 4=extremely). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition

    Time frame: Pre-dose, 40 minutes and 90 minutes post-dose up to Week 4

  3. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

    Time frame: From Week 2 up to Week 13

  4. Number of Participants with Abnormalities in Vital Signs

    Number of participants with abnormalities in vital signs (pulse/heart rate, blood pressure, and body temperature) will be reported.

    Time frame: From Week 2 up to Week 13

  5. Columbia Suicide Severity Rating (C-SSRS) Score

    C-SSRS is semi structured clinician-administered questionnaire designed to solicit the occurrence, severity, and frequency of suicide-related ideation and behaviors. The maximum score assigned for each participant will also be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity.

    Time frame: Up to Week 13

  6. Clinical Global Assessment of Discharge Readiness (CGADR) Score

    The CGADR will be used to measure the participant's current clinical status and is the clinician's assessment of the readiness to be discharged from the study site. The clinician will answer "Yes" or "No" to the question "Is the participant considered ready to be discharged based on their overall clinical status (example, sedation, blood pressure, and other adverse events)?"

    Time frame: From Week 2 up to Week 13

07

Study locations

5 sites
  • Yale University
    New Haven, Connecticut 06511, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21204, United States
  • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2022; primary completion for Jun 2023, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Mar 7, 2022
StartEst.
Sep 1, 2022
Primary completionEst.
Jun 7, 2023
CompletionEst.
Jun 7, 2023
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05268497
Responsible party
Sponsor
First posted
Mar 7, 2022
Start date
Sep 1, 2022 (estimated)
Primary completion
Jun 7, 2023 (estimated)
Completion
Jun 7, 2023 (estimated)
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion